Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

No Alzheimer's benefits in supplements - NIH panel

This article was originally published in The Tan Sheet

Executive Summary

Data do not support the association of dietary supplement intake and drug regimens with reduced risk of Alzheimer's disease, says a National Institutes of Health panel. Following a state-of-the-science conference April 26-28 in Bethesda, Md., the panel said in a 1statement that longer chain omega-3 fatty acids demonstrate some reduced risk of cognitive decline in longitudinal studies and "may provide new insight into the prevention or delay of cognitive decline or Alzheimer's." Other nutritional interventions, including folate, beta-carotene and vitamins B, E and C, show no consistent cognitive benefits, the panel said. Products touting support for brain and memory health products are a growing supplement segment (2"The Tan Sheet" Dec. 21, 2009)

You may also be interested in...



Ovos Plots Vivimind Cognitive Supplement Launch, Awaits FDA Reply

Ovos Natural Health plans a 2010 U.S. launch of its Vivimind cognitive health supplement, contingent upon FDA's go-ahead

Warning Letter Roundup & Recap – January 2023

The US Food and Drug Administration published three device-related warning letters in January – two that went to divisions of endoscope vendor Olympus, and one to a Maryland vision treatment firm.

US FDA Urged To Improve Messaging To Professional Societies On Accelerated Approval Withdrawals

Lengthy withdrawal process creates an opening for the FDA to better convey its concerns about a medicine’s benefit-risk profile in a way that impacts prescribing guidelines, Johns Hopkins’ Joshua Sharfstein says; CDER’s Jacqueline Corrigan-Curay says new expedited withdrawal procedures under omnibus law appear more ‘streamlined’ than those followed for Makena.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS104072

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel